Hepatitis B virus-specific CD4+ T-cell receptor (HBV-specific CD4+ TCR)

Hepatitis B virus-specific CD4+ T-cell receptors (TCRs) are membrane-bound heterodimers that recognize specific HBV-derived peptides presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells or infected hepatocytes (Bertoletti & Ferrari, 2012, Journal of Hepatology). These receptors are central to the orchestration of the adaptive immune response against HBV, facilitating the activation of CD8+ cytotoxic T-cells and the maturation of B-cells into antibody-secreting plasma cells (Gehring et al., 2014, Progress in Molecular Biology and Translational Science). In chronic hepatitis B (CHB) infection, the endogenous HBV-specific CD4+ T-cell response is typically characterized by functional exhaustion and low frequency, contributing to viral persistence (Ye et al., 2015, Cell Death & Disease). Therapeutic strategies targeting these TCRs involve the development of TCR-engineered T-cell (TCR-T) therapies, where patient-derived T-cells are modified to express high-affinity HBV-specific CD4+ TCRs to restore antiviral immunity (Wisskirchen et al., 2019, Current Opinion in Virology). These engineered cells aim to recognize viral epitopes from proteins such as the HBV core (HBcAg) or surface (HBsAg) antigens, potentially leading to functional cure or treatment of HBV-related hepatocellular carcinoma (Tan et al., 2021, Journal of Gastroenterology and Hepatology).

Other names

HBV-specific CD4+ T-cell receptorMHC class II-restricted HBV-specific TCRHepatitis B virus-specific CD4+ TCR

Recognition of HBV-derived peptides presented on MHC Class II molecules, triggering CD4+ T-cell activation and downstream immune effector functions.